Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-american-society-of-clinical-oncology-annual-meeting-302126568.html
https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-barclays-26th-annual-global-healthcare-and-leerink-partners-global-biopharma-conferences-302082067.html
https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302077072.html
https://www.prnewswire.com/news-releases/karyopharm-reports-fourth-quarter-and-full-year-2023-financial-results-and-highlights-recent-company-progress-302074918.html
https://www.prnewswire.com/news-releases/karyopharm-announces-preliminary-unaudited-2023-revenue-and-2024-objectives-302028197.html
https://www.prnewswire.com/news-releases/karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-phase-1-study-of-selinexor-60mg-and-ruxolitinib-in-jak-inhibitor-jaki-naive-myelofibrosis-patients-with-no-svr-or-tss-progressions-observed--302010754.html
https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302001328.html
https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301980727.html
https://www.prnewswire.com/news-releases/karyopharm-announces-new-preliminary-data-in-overall-survival-os-in-selinexor-treated-patients-with-advanced-or-recurrent-tp53-wild-type-endometrial-cancer-as-part-of-pre-specified-exploratory-subgroup-analysis-of-the-siendo-stu-301977796.html
https://www.prnewswire.com/news-releases/karyopharm-announces-presentations-at-the-65th-american-society-of-hematology-annual-meeting-and-exposition-ash-301975236.html